Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition-Reference-Cited by-同舟云学术

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

Published:2021-05 Issue: Volume:148 Page:61-75
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Knispel Sarah,Gassenmaier Maximilian,Menzies Alexander M.,Loquai Carmen,Johnson Douglas B.,Franklin Cindy^ORCID,Gutzmer Ralf^ORCID,Hassel Jessica C.,Weishaupt Carsten,Eigentler Thomas,Schilling Bastian^ORCID,Schummer Patrick^ORCID,Sirokay Judith^ORCID,Kiecker Felix,Owen Carina N.^ORCID,Fleischer Maria I.,Cann Christopher,Kähler Katharina C.,Mohr Peter,Bluhm Leonie,Niebel Dennis^ORCID,Thoms Kai-Martin,Goldinger Simone M.,Reinhardt Lydia^ORCID,Meier Friedegund,Berking Carola^ORCID,Reinhard Raphael,Susok Laura,Ascierto Paolo A.^ORCID,Drexler Konstantin,Pföhler Claudia,Tietze Julia,Heinzerling Lucie,Livingstone Elisabeth^ORCID,Ugurel Selma,Long Georgina V.^ORCID,Stang Andreas,Schadendorf Dirk,Zimmer Lisa^ORCID

Funder

Novartis Pharma GmbH

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma;Flaherty;J Clin Oncol,2013

2. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N Engl J Med,2015

3. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma;Larkin;N Engl J Med,2014

4. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial;Dummer;Lancet Oncol,2018

5. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma;Journal of Clinical Oncology;2024-08-20

2. Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers;Cancer Drug Resistance;2024-05-13

3. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma;European Journal of Cancer;2024-05

4. Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis;Expert Review of Anticancer Therapy;2024-03-29

5. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy;Cancer Immunology, Immunotherapy;2024-03-02